Market Doc
Long/short equity, healthcare

Isis: Long-Term Kynamro Adverse Events May Apply To Entire ISIS 2.0 Pipeline


ISIS Pharmaceuticals (ISIS) is a dynamic biotechnology company focused on the development of antisense oligonucleotides (ASOs) as drugs. Its chief antisense oligonucleotide (ASO) is Kynamro (mipomersen), which is used to lower cholesterol. After reviewing available long-term data on Kynamro, I will show that Kynamro has qualities that make for a very poor drug because:

1. It is poorly tolerated.

2. It is immunogenic.

3. The immune response is associated with increased adverse events.

4. Long-term use leads to increased adverse events.

As acknowledged by ISIS CEO Stanley Crooke in a recent review, Kynamro (mipomersen) is a representative molecule of ISIS second generation antisense oligonucleotides (ASOs). He states:

Mipomersen is representative of second generation ASOs. As all ...
Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
  • Access Top Ideas, chosen by Seeking Alpha’s editors
  • Filter long and short ideas by market cap and sector
  • Get Coverage of over 5,000 stocks, many of which have little or no coverage elsewhere
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO." Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else." Patrick Rice, Mainstay Capital Management
100% Satisfaction Guaranteed
Money back guarantee. Seeking Alpha PRO members receive a no-questions-asked refund for membership on months paid and not used. Details